Coherus BioSciences (CHRS)

• Market cap: $105M
• 1 day: -7.48%
• 5 days: -9.33%
• 1 month: -21.84%
• 3 months: -43.68%
• 6 months: -30.25%
• Year to date: -35.24%
• 1 year: -60.58%
• 5 years: -93.94%
• 10 years: -96.87%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Employees: 235

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

4,679% more call options, than puts

Call options by funds: $7.36M | Put options by funds: $154K

13% more capital invested

Capital invested by funds: $80M [Q3] → $90M (+$10M) [Q4]

9% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 33

5% less funds holding

Funds holding: 129 [Q3] → 122 (-7) [Q4]

10.2% less ownership

Funds ownership: 66.85% [Q3] → 56.65% (-10.2%) [Q4]

17% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 35

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 672% upside
• Avg. target: $7 672% upside
• High target: $7 672% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 46 / 180 met price target

672% upside $7

Buy Reiterated

11 Mar 2025